Literature DB >> 2266171

Type II oestrogen binding sites in human colorectal carcinoma.

M Piantelli1, R Ricci, L M Larocca, A Rinelli, A Capelli, S Rizzo, G Scambia, F O Ranelletti.   

Abstract

Seven cases of colorectal adenocarcinomas were investigated for the presence of oestrogen receptors and progesterone receptors. The tumours specifically bound oestradiol. This binding almost exclusively resulted from the presence of high numbers of type II oestrogen binding sites. Oestrogen receptors were absent or present at very low concentrations. Immunohistochemical investigation of nuclear oestrogen receptors gave negative results. This indicates that antioestrogen receptor antibodies recognise oestrogen receptors but not type II oestrogen binding sites. The presence of specific type II oestrogen binding sites and progesterone binding offers further evidence for a potential role for these steroids and their receptors in colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2266171      PMCID: PMC502973          DOI: 10.1136/jcp.43.12.1004

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  22 in total

1.  Breast cancer and associated extramammary malignant neoplasms.

Authors:  J B Herrmann
Journal:  Am J Surg       Date:  1972-11       Impact factor: 2.565

2.  Type II estrogen receptors in the papillary cystic tumor of the pancreas.

Authors:  A Carbone; F O Ranelletti; A Rinelli; F M Vecchio; L Lauriola; M Piantelli; A Capelli
Journal:  Am J Clin Pathol       Date:  1989-11       Impact factor: 2.493

3.  Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids.

Authors:  L M Larocca; M Piantelli; G Leone; S Sica; L Teofili; P B Panici; G Scambia; S Mancuso; A Capelli; F O Ranelletti
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

4.  Type II estrogen-binding sites and 17 beta-hydroxysteroid dehydrogenase activity in human peripheral blood mononuclear cells.

Authors:  F O Ranelletti; M Piantelli; A Carbone; A Rinelli; G Scambia; P B Panici; S Mancuso
Journal:  J Clin Endocrinol Metab       Date:  1988-11       Impact factor: 5.958

5.  Oestrogen receptors in colorectal carcinoma.

Authors:  P M Dawson; S Shousha; S D Blair; G D Carter; J Jones; J Alaghband-Zadeh; N A Theodorou
Journal:  J Clin Pathol       Date:  1990-02       Impact factor: 3.411

6.  The influence of parity and exogenous female hormones on the risk of colorectal cancer.

Authors:  F G Davis; S E Furner; V Persky; M Koch
Journal:  Int J Cancer       Date:  1989-04-15       Impact factor: 7.396

7.  Estradiol and progesterone receptors in malignant gastrointestinal tumors.

Authors:  V Sica; E Nola; E Contieri; R Bova; M T Masucci; N Medici; A Petrillo; A Weisz; A M Molinari; G A Puca
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

8.  Estrogen and progestin receptors in colonic cancer?

Authors:  T Wobbes; L V Beex; A M Koenders
Journal:  Dis Colon Rectum       Date:  1984-09       Impact factor: 4.585

9.  Nuclear and cytosolic estrogen receptors in human colon carcinoma and in surrounding noncancerous colonic tissue.

Authors:  A Francavilla; A Di Leo; L Polimeno; D Conte; M Barone; G Fanizza; C Chiumarulo; G Rizzo; M Rubino
Journal:  Gastroenterology       Date:  1987-12       Impact factor: 22.682

10.  Progesterone receptor is constitutively expressed in chicken intestinal mesothelium and smooth muscle.

Authors:  S Salomaa; A Pekki; T Sannisto; T Ylikomi; P Tuohimaa
Journal:  J Steroid Biochem       Date:  1989       Impact factor: 4.292

View more
  7 in total

1.  Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.

Authors:  Barry M Markaverich; Mary Vijjeswarapu; Kevin Shoulars; Mary Rodriguez
Journal:  J Steroid Biochem Mol Biol       Date:  2010-06-15       Impact factor: 4.292

2.  Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.

Authors:  Kevin Shoulars; Mary Ann Rodriguez; Trellis Thompson; Barry M Markaverich
Journal:  J Steroid Biochem Mol Biol       Date:  2009-10-27       Impact factor: 4.292

3.  Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites.

Authors:  G Scambia; F O Ranelletti; P Benedetti Panici; M Piantelli; G Bonanno; R De Vincenzo; G Ferrandina; L Pierelli; A Capelli; S Mancuso
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors.

Authors:  S Singh; M C Sheppard; M J Langman
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

5.  Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells.

Authors:  Barry M Markaverich; Kevin Shoulars; Mary Ann Rodriguez
Journal:  Int J Biomed Sci       Date:  2011

6.  Multiple Sites of Type II Site Ligand (Luteolin and BMHPC) Regulation of Gene Expression in PC-3 Cells.

Authors:  Barry M Markaverich; Mary Vijjeswarapu
Journal:  Int J Biomed Sci       Date:  2012-12

7.  Effects of coumestrol on estrogen receptor function and uterine growth in ovariectomized rats.

Authors:  B M Markaverich; B Webb; C L Densmore; R R Gregory
Journal:  Environ Health Perspect       Date:  1995-06       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.